- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02156570
DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral) (DARE-C II)
An Interferon Sparing Strategy of Sofosbuvir Plus Ribavirin for the Treatment of Recently Acquired Hepatitis C Infection
The purpose of the study is to examine whether patients who have acute or early chronic hepatitis C virus (HCV) infection can be treated effectively and safely with an interferon-sparing regimen that combines a new direct acting antiviral drug (sofosbuvir) with one of the standard treatments for chronic hepatitis C (ribavirin). In particular, this study will investigate whether treatment of acute or early chronic HCV can be shortened. The study will assess efficacy by looking at the proportion of people who clear the virus (have no virus detectable in their blood) at the end of treatment, and 1, 3 and 6 months after treatment.
The hypothesis is that short course (6 weeks) dual therapy using sofosbuvir and RBV will result in successful virological eradication in the majority (≥80%) of subjects treated for recently acquired HCV.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
To evaluate the efficacy, safety and acceptability of an interferon-sparing strategy with sofosbuvir and ribavirin for the treatment of recently acquired HCV infection.
An open label single arm multicentre study Treatment of participants: Sofosbuvir 400mg daily with weight based ribavirin (1000mg <75 kg, 1200mg >/= 75kg) Duration of treatment will be 6 weeks for all subjects followed by 52 weeks of observational follow-up Total study duration = 58 weeks Primary endpoint: SVR 12
Type d'étude
Inscription (Anticipé)
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
New South Wales
-
Sydney, New South Wales, Australie, 2010
- St Vincent's Hospital
-
-
South Australia
-
Adelaide, South Australia, Australie, 5000
- Royal Adelaide Hospital
-
-
Victoria
-
Melbourne, Victoria, Australie, 3050
- Royal Melbourne Hospital
-
Melbourne, Victoria, Australie, 3004
- Alfred Hospital
-
-
-
-
Grafton
-
Auckland, Grafton, Nouvelle-Zélande, 1023
- Auckland City Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Provision of written informed consent
- Male and female patients aged 18 years and above
- Willing to use two effective methods of contraception during the treatment period and 24 weeks post.
- HBsAg negative
- Detectable HCV RNA at screening (>10,000 IU/ml), and in the opinion of the investigator is unlikely to demonstrate spontaneous viral clearance
- Compensated liver disease (Child-Pugh A)
- Negative pregnancy test at screening and 24 hours prior to first dose of study drugs
- Medically stable on the basis of physical examination, medical history and vital signs
- Adequate English to provide reliable responses to the study questionnaires
- Recent hepatitis C infection, as defined by: A) i) First anti-HCV Ab or HCV RNA positive within the previous 6 months and ii) Documented anti-HCV Ab negative within the 24 months prior to anti-HCV antibody positive result, OR B) i) First anti-HCV Ab or HCV RNA positive within the previous 6 months and ii) acute clinical hepatitis (jaundice or ALT> 10 X ULN) within the previous 12 months prior to first positive HCV antibody or HCV RNA, with no other cause of acute hepatitis identifiable
If co-infection with HIV is documented, the subject must meet the following criteria:
- Antiretroviral (ARV) untreated for >8 weeks preceding screening visit with CD4 T cell count >500 cells/mm3 OR
- On a stable ARV regimen for >8 weeks prior to screening visit, with CD4 T cell count >200 cells/mm3 and an undetectable plasma HIV RNA level.
Exclusion Criteria:
- Standard exclusions to RBV therapy
- Pregnancy/lactation or male subjects whose female partners are pregnant
- Subject has a history of decompensated liver disease: history of ascites, hepatic encephalopathy, or bleeding oesophageal varices, and/or any of the following screening laboratory results: a.INR of ≥1.5; Serum albumin <3.3 g/dL; Serum total bilirubin >1.8 times upper limit of normal, unless isolated in subjects with Gilbert's syndrome.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Sofosbuvir and ribavirin
Sofosbuvir tablet 400 mg daily Ribavirin tablet weight based dosing (1000mg <75 kg, 1200mg >/= 75kg) daily Treatment will be for 6 weeks in all participants. |
Sofosbuvir 400mg daily plus weight-based dosing ribavirin (1000mg <75kg, 1200mg >/= 75 kg) Treatment will be for 6 weeks in all participants.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
SVR 12
Délai: 12 weeks post treatment
|
Proportion of patients with undetectable HCV RNA by TaqMan 12 weeks after therapy completion (SVR 12 - Week 18)
|
12 weeks post treatment
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
SVR 24
Délai: 24 weeks post treatment
|
Proportion of patients with undetectable HCV RNA by TaqMan 24 weeks after therapy completion (SVR 24 - Week 30)
|
24 weeks post treatment
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
End of treatment response
Délai: End of treatment week 6
|
Proportion of patients with undetectable HCV RNA at end of therapy (ETR - week 6)
|
End of treatment week 6
|
SVR 4
Délai: 4 weeks post treatment
|
Proportion of patients with undetectable HCV RNA by TaqMan 4 weeks after therapy completion (SVR 4 - Week 10)
|
4 weeks post treatment
|
Follow up 1 year
Délai: 1 year post treatment
|
Proportion of patients with undetectable HCV RNA at end of study follow-up (FU1 - Week 58)
|
1 year post treatment
|
Undetectable HCV RNA
Délai: Week 1, 2, 3 and 4 of treatment
|
Proportion of patients with undetectable HCV RNA at weeks 1, 2, 3 and 4
|
Week 1, 2, 3 and 4 of treatment
|
Indicators of toxicity (ALT, HB, Neutrophils, Platelets)
Délai: Baseline until week 4 of treatment
|
To evaluate indicators of toxicity (ALT, HB, Neutrophils, Platelets) during therapy
|
Baseline until week 4 of treatment
|
Plasma ribavirin levels and haemoglobin
Délai: Baseline to week 4 of treatment
|
To correlate plasma ribavirin levels with treatment outcome and changes in haemoglobin during therapy
|
Baseline to week 4 of treatment
|
Incidence of reinfection
Délai: End of treatment until follow up 1 year
|
Incidence of reinfection after documented SVR
|
End of treatment until follow up 1 year
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Gail Matthews, MbChB FRACP, Kirby Institute
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies du système digestif
- Infections par virus à ARN
- Maladies virales
- Infections
- Infections transmissibles par le sang
- Maladies transmissibles
- Maladies du foie
- Infections à Flaviviridae
- Hépatite, virale, humaine
- Infections à entérovirus
- Infections à Picornaviridae
- Hépatite
- Hépatite A
- Hépatite C
- Mécanismes moléculaires de l'action pharmacologique
- Agents anti-infectieux
- Agents antiviraux
- Antimétabolites
- Sofosbuvir
- Ribavirine
Autres numéros d'identification d'étude
- VHCRP1206
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Sofosbuvir and ribavirin
-
hearX GroupUniversity of PretoriaComplété
-
Oregon Health and Science UniversityNational Institute on Aging (NIA)ComplétéDémence | Maladie d'Alzheimer | Membres de la famille | Épuisement professionnel des soignantsÉtats-Unis
-
Dalarna UniversityUppsala University; The Swedish Research CouncilRecrutementDémence | Déficience cognitive légère | Démence mixte | Démence de type Alzheimer | Déficience cognitive subjective | Démence SénileSuède
-
University of Illinois at ChicagoRecrutementPersonnes âgées en bonne santéÉtats-Unis
-
Vastra Gotaland RegionDetectivio ABComplété
-
University of South CarolinaActif, ne recrute pasFrénésie alimentaire | L'image corporelle | Comportement alimentaire | Nutrition, Santé | Alimentation désordonnéeÉtats-Unis
-
National University of MalaysiaComplétéApplications mobilesMalaisie
-
Institut de Cancérologie de la LoireComplété
-
University of Illinois at Urbana-ChampaignInconnueBlessure de chute | Prévention des chutes | Sécurité antichute
-
Samsung ElectronicsComplétéVieilli | Adultes | Moyen-Âge | Âgé, 80 ans et plusCorée, République de